Krista Davis Sells 1,763 Shares of ANI Pharmaceuticals (NASDAQ:ANIP) Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) SVP Krista Davis sold 1,763 shares of the business’s stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $91.10, for a total value of $160,609.30. Following the completion of the sale, the senior vice president directly owned 62,896 shares in the company, valued at $5,729,825.60. This trade represents a 2.73% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

ANI Pharmaceuticals Price Performance

ANIP opened at $91.88 on Thursday. The firm has a market cap of $1.99 billion, a PE ratio of -119.32 and a beta of 0.61. The stock has a 50-day moving average price of $72.27 and a 200-day moving average price of $66.56. ANI Pharmaceuticals, Inc. has a 1 year low of $52.50 and a 1 year high of $92.65. The company has a debt-to-equity ratio of 1.39, a current ratio of 2.54 and a quick ratio of 1.96.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its quarterly earnings data on Friday, August 8th. The specialty pharmaceutical company reported $1.80 EPS for the quarter, beating the consensus estimate of $1.42 by $0.38. The company had revenue of $211.37 million for the quarter, compared to the consensus estimate of $187.18 million. ANI Pharmaceuticals had a negative net margin of 1.37% and a positive return on equity of 25.03%. ANI Pharmaceuticals’s revenue for the quarter was up 53.2% on a year-over-year basis. During the same period in the prior year, the firm posted $1.02 EPS. Sell-side analysts predict that ANI Pharmaceuticals, Inc. will post 3.86 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

ANIP has been the topic of several analyst reports. Wall Street Zen upgraded shares of ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, August 16th. Piper Sandler reissued an “overweight” rating and issued a $94.00 target price on shares of ANI Pharmaceuticals in a report on Friday, August 8th. Guggenheim reaffirmed a “buy” rating and set a $86.00 price target on shares of ANI Pharmaceuticals in a report on Monday, May 12th. HC Wainwright reaffirmed a “buy” rating and set a $93.00 price objective (up from $84.00) on shares of ANI Pharmaceuticals in a research report on Friday, August 8th. Finally, Zacks Research upgraded ANI Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Thursday, August 21st. Two analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat, ANI Pharmaceuticals currently has a consensus rating of “Buy” and a consensus price target of $84.75.

Institutional Investors Weigh In On ANI Pharmaceuticals

Large investors have recently made changes to their positions in the company. Advisors Asset Management Inc. bought a new stake in shares of ANI Pharmaceuticals during the 1st quarter valued at about $28,000. Caitong International Asset Management Co. Ltd grew its stake in shares of ANI Pharmaceuticals by 4,636.4% during the 2nd quarter. Caitong International Asset Management Co. Ltd now owns 521 shares of the specialty pharmaceutical company’s stock valued at $34,000 after purchasing an additional 510 shares during the period. Newbridge Financial Services Group Inc. grew its stake in shares of ANI Pharmaceuticals by 200.0% during the 2nd quarter. Newbridge Financial Services Group Inc. now owns 600 shares of the specialty pharmaceutical company’s stock valued at $39,000 after purchasing an additional 400 shares during the period. State of Wyoming bought a new stake in shares of ANI Pharmaceuticals during the 2nd quarter valued at about $50,000. Finally, National Bank of Canada FI bought a new stake in shares of ANI Pharmaceuticals during the 1st quarter valued at about $79,000. 76.05% of the stock is currently owned by institutional investors.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.